TY  - JOUR 
AU  - Steegmann, Juan Luís
AU  - Odriozola, Jesús
AU  - Rodriguez Salvanés, Francisco
AU  - Giraldo, Pilar
AU  - García Laraña, José
AU  - Ferro, María Teresa
AU  - Benítez, Esmeralda
AU  - Pérez-Pons, Concepción
AU  - Giralt, Manuel
AU  - Escribano, Luís
AU  - Lavilla Rubira, Esperanza
AU  - Miguel, Amparo
AU  - Areal Méndez, Carlos
AU  - Pérez Encinas, Manuel Mateo
AU  - Abad, Ana
AU  - Maldonado, Juan
AU  - Massagué, Isabel
AU  - Fernández-Rañada, José María
PY  - 1999
SN  - 0390-6078
UR  - http://hdl.handle.net/20.500.11940/22541
AB  - [EN] BACKGROUND AND OBJECTIVE: Interferon-a (IFN) is increasingly being used as the drug of choice in chronic myeloid leukemia patients. The main objectives of the study were to study the influence of the classic prognostic variables and response to...
LA  - eng
KW  - Aged
KW  - Spain
KW  - Interferon alpha-2
KW  - Cytogenetic Analysis
KW  - Prognosis
KW  - Thrombocytopenia
KW  - Philadelphia Chromosome
KW  - Time Factors
KW  - Basophils
KW  - Treatment Outcome
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - Interferon-alpha
KW  - Survival Rate
KW  - Leukemia, Myeloid, Chronic-Phase
TI  - Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML
T2  - Haematologica
M2  - 978
KW  - CHULA
KW  - CHUF
KW  - CHUS
VL  - 84
ER  -